BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $27
Catalyst Pharmaceuticals Analyst Ratings
Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $31
Catalyst Pharmaceuticals Analyst Ratings
Truist Adjusts Price Target on Catalyst Pharmaceuticals to $30 From $25, Maintains Buy Rating
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $26 Price Target
HC Wainwright & Co. : The Catalyst Pharmaceuticals (CPRX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $24.00 to $26.00.
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Citigroup Initiates Coverage On Catalyst Pharmaceuticals With Buy Rating, Announces Price Target of $27
Catalyst Pharmaceuticals Analyst Ratings
BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target Is $23
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $27 Price Target
Catalyst Pharmaceuticals Analyst Ratings